Navigation Links
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Date:2/11/2010

ABBOTT PARK, Ill., Feb. 11 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir).  The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.  The Norvir tablets and the Norvir soft-gelatin capsules both contain 100 mg of ritonavir.  While the rate of drug absorbed is different, there is no requirement for dosage change.  Norvir is used in combination with other antiretroviral medications to treat HIV.  All forms of Norvir, including the soft-gel capsule and liquid form, remain available in the United States.

"Norvir has been a critical component of HIV treatment for many patients.  The innovation behind the development of the Norvir tablet is the direct result of years of effort by Abbott scientists to address the needs of people living with HIV," said Scott Brun, M.D., divisional vice president, infectious disease development, Global Pharmaceutical Research and Development, Abbott.  "Abbott has been dedicated to finding new and more convenient ways for patients to manage their HIV through the development of novel diagnostics testing methods and medications for more than 20 years."

Abbott scientists evaluated several candidate formulations before developing the final Norvir tablet formulation.  The

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, announced the start of a phase 1 ... will explore the safety, pharmacokinetics,pharmacodynamics and anti-tumor activity ... MT110 targets the epithelial cell adhesion molecule ...
... an oncolytic product, WOBURN, Mass., April 22 ... treatments for cancer and the prevention,of infectious disease, ... (FDA) has approved the design of a single, ... OncoVEX(GM-CSF) in,previously treated patients with metastatic melanoma. The ...
Cached Medicine Technology:Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 2Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 3Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 4Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 5BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 2BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 3
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business is ... company announces big discounts on its bamboo mats , ... is the world’s leader in bamboo flooring. According to ... 20, 2015. , The bamboo mats are made from ... All the bamboo strips for the mats are boiled ...
(Date:12/25/2014)... News) -- The risk of burns from fires and ... to be extra cautious, an expert says. "Between ... increase in patients coming in with burns," said Dr. ... Firefighters Burn Center of Stony Brook University Hospital in ... joy, but if not careful, could quickly turn tragic," ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... ... for Entries is now open. , ... Rosemont, IL (Vocus) July 9, 2009 -- The American Academy of Orthopaedic Surgeons (AAOS) ... These awards recognize excellence in accurate reporting on musculoskeletal health issues and healthy behaviors in ...
... and enhanced caregiver training , , NEW YORK, ... New York, NY, and Samarion Inc., Jackson, MS, announced ... address the critical need for optimal dementia care through ... for healthcare professionals. , , Samarion,s Enterprise Quality ...
... the impression that "Spice Gold" is strongly addictive. In ... ( Dtsch Arzteblatt Int 2009: 106[27]: 464-7), Ulrich ... describe a young man who developed physical withdrawal symptoms ... a dependence syndrome. Since 22 January 2009, ...
... July 9 Specialty Hospitals of America ... official opening of new beds in the Skilled Nursing Facility (SNF) ... of Washington, no matter where they live, should have access to ... of America (SHA) and Chairman and President of UMC. "The ...
... Women lawmakers will participate in the first Congressional Women,s Softball Game, ... held on Tuesday, July 14 at Guy Mason Field. ... Proceeds from the game will help the Young Survival Coalition (YSC) ... breast cancer. , , Members of Congress from ...
... July 2009 As soccer continues to grow in popularity, ... well. Certain injuries fall into gender-based patterns and ... underlying causes that could help lead to better treatment, ... Data presented at this year,s American Orthopaedic Society ...
Cached Medicine News:Health News:Got Moving Stories? Calling All Reporters, Writers, Producers and Editors 2Health News:Got Moving Stories? Calling All Reporters, Writers, Producers and Editors 3Health News:Alzheimer's Foundation of America and Samarion(SM) Form Strategic Alliance to Enhance Care for Individuals with Dementia 2Health News:Alzheimer's Foundation of America and Samarion(SM) Form Strategic Alliance to Enhance Care for Individuals with Dementia 3Health News:Specialty Hospitals of Washington Adds Additional Skilled Nursing Facility Beds at United Medical Center in South East DC 2Health News:First Annual Congressional Women's Softball Game to Benefit the Young Survival Coalition 2Health News:First Annual Congressional Women's Softball Game to Benefit the Young Survival Coalition 3Health News:Motion analysis helps soccer players get their kicks 2Health News:Motion analysis helps soccer players get their kicks 3
CVC 223 is an assayed quality control material used for confirming the calibration and linearity of CO-Oximeter instrumentation....
... control material used for monitoring the performance of ... for specific use on Bayer analyzers that measure ... 270) and the AVOX Systems CO-Oximeters (4000 and ... the IRMA TRUpoint. CC 527 is available in ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
... is a reagent and probe system used ... high throughput plate based system is a ... a unique approach for RNA detection and ... branched DNA (bDNA) technology. Branched DNA allows ...
Medicine Products: